If you are a biotech stock investor, you have probably realized that you are in a market awash with a lot of good news these days. But investors should be cautious, as the sector is also rife with risk.
Shares in the biotech sector surged 9.3 percent last week on the Taiwan Stock Exchange, compared with a 3.08 percent increase on the benchmark TAIEX.
Virtually every week over the past month, positive news was released to assure investors that the biotech sector could one day become another object of pride for the nation, along the lines of the information technology industry.
Last month, for example, the legislature passed the Biotech and New Pharmaceutical Development Act (
Then came the news that the US firm Genentech Inc might set up a research joint venture at the Hsinchu Biochemical Science Park to develop AIDS treatments, with Taiwanese-American researcher David Ho (
Investors were also encouraged by news that the government would spend NT$12.1 billion on infrastructure in the proposed Nangang Biotech Park in Taipei and establish a US$1 billion biotech joint venture with foreign investors, with Taiwan owning a 40 percent stake.
Granted, there is consensus among the government, industry and academia that the nation must shift from traditional labor-intensive manufacturing to capital-intensive biotech.
Academia Sinica even praised the enactment of the new law as a "turning point for Taiwan" and said it hoped to see the biotech sector become the nation's next star industry. But there are a number of hurdles to overcome.
One problem is whether Taiwanese companies have sufficient funds to develop new drugs. Most local firms are much smaller than their foreign rivals. Moreover, bringing a new drug to the market can take a company one to two decades and cost hundreds of millions of dollars.
Companies that intend to market a new drug must go through a complex, time-consuming and very expensive process, including the initial experimental study, three phases of clinical trials and a phase VI clinical study to monitor a drug's effects during a post-marketing period.
If a new drug does reach the market, the company could profit by licensing the technology. If not, the whole endeavor could end up as a waste of money endangering the very survival of the company.
On a positive note, the new law provides more tax exemptions to companies interested in biotech development. As much as 35 percent of a company's investment in R&D and personnel training will be exempted from business tax for a period of five years.
But that is not enough. The government must also provide an environment that is conducive to attracting scientists from around the world, as international collaboration is vital. Absent these, the nation will lag far behind neighbors including South Korea, Singapore, China and India.
Known for its entrepreneurial spirit and blessed with a vast pool of biotech and pharmaceutical talent, Taiwan faces a golden opportunity through outsourcing.
But are the government and companies ready to compete internationally for this US$800 billion market? Are potential investors?
President William Lai (賴清德) recently attended an event in Taipei marking the end of World War II in Europe, emphasizing in his speech: “Using force to invade another country is an unjust act and will ultimately fail.” In just a few words, he captured the core values of the postwar international order and reminded us again: History is not just for reflection, but serves as a warning for the present. From a broad historical perspective, his statement carries weight. For centuries, international relations operated under the law of the jungle — where the strong dominated and the weak were constrained. That
The Executive Yuan recently revised a page of its Web site on ethnic groups in Taiwan, replacing the term “Han” (漢族) with “the rest of the population.” The page, which was updated on March 24, describes the composition of Taiwan’s registered households as indigenous (2.5 percent), foreign origin (1.2 percent) and the rest of the population (96.2 percent). The change was picked up by a social media user and amplified by local media, sparking heated discussion over the weekend. The pan-blue and pro-China camp called it a politically motivated desinicization attempt to obscure the Han Chinese ethnicity of most Taiwanese.
On Wednesday last week, the Rossiyskaya Gazeta published an article by Chinese President Xi Jinping (習近平) asserting the People’s Republic of China’s (PRC) territorial claim over Taiwan effective 1945, predicated upon instruments such as the 1943 Cairo Declaration and the 1945 Potsdam Proclamation. The article further contended that this de jure and de facto status was subsequently reaffirmed by UN General Assembly Resolution 2758 of 1971. The Ministry of Foreign Affairs promptly issued a statement categorically repudiating these assertions. In addition to the reasons put forward by the ministry, I believe that China’s assertions are open to questions in international
The Legislative Yuan passed an amendment on Friday last week to add four national holidays and make Workers’ Day a national holiday for all sectors — a move referred to as “four plus one.” The Chinese Nationalist Party (KMT) and the Taiwan People’s Party (TPP), who used their combined legislative majority to push the bill through its third reading, claim the holidays were chosen based on their inherent significance and social relevance. However, in passing the amendment, they have stuck to the traditional mindset of taking a holiday just for the sake of it, failing to make good use of
RSS